Manning Meredith 4

What Happened

• Meredith Manning, Chief Commercial Officer of Soleno Therapeutics (SLNO), was granted a total of 61,400 restricted stock units (RSUs) on January 21, 2026: 28,600 RSUs (reported as A) and 32,800 RSUs (reported as a derivative award). Both grants show an acquisition price of $0.00 (awarded, not purchased), so there was no cash paid for the awards.

Key Details

• Transaction date: 2026-01-21; Form 4 filed 2026-01-23 (appears timely).
• Awards: 28,600 RSUs (F1) + 32,800 RSUs (F2) = 61,400 RSUs total; reported price $0.00.
• Vesting: F1 states 100% of the 28,600 RSUs vest on December 15, 2027, subject to continued service. F2 notes the 32,800 RSUs are subject to their applicable vesting schedules and conditions.
• Additional disclosure (F3): the filing references options that vest 1/48th on 2/1/2026 and monthly thereafter (this pertains to other option awards held by the reporting person).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction code: A = Award/Grant; one award is reported as a derivative (contingent right to receive shares).

Context

• RSUs are awards that give a contingent right to receive shares in the future if vesting conditions are met; they are not an immediate cash purchase or sale. The grants reported here are typical compensation awards and do not by themselves indicate a buy or sell signal in the market.